Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AI Enhances Early-Stage Detection of Esophageal Cancers During Routine Endoscopy

By HospiMedica International staff writers
Posted on 02 Aug 2024

Endoscopy serves as the principal technique for identifying asymptomatic esophageal squamous cell carcinoma (ESCC) and precancerous lesions. More...

Detecting early-stage esophageal cancers, which respond better to treatment, remains a significant challenge due to their subtle presentation. Enhancing the detection rates of such early stages is crucial. Now, a new study has demonstrated that integrating a deep learning system into routine endoscopy can significantly improve the detection of early-stage esophageal cancers.

The large-scale randomized controlled trial (RCT), conducted by researchers at Taizhou Hospital (Zhejiang, China), evaluated the effectiveness of a deep learning–based system named ENDOANGEL-ELD for detecting esophageal cancer. The results published in Science Translational Medicine reveal that this AI system nearly doubled the detection capability of clinicians in identifying high-risk esophageal lesions, including both cancerous and precancerous conditions, compared to traditional unassisted endoscopy.

In the trial, 3,117 patients were randomly assigned to undergo either AI-assisted or standard endoscopy. The findings indicated a significant improvement in detection rates of high-risk esophageal lesions when using the AI system, with detection rates of 1.8% compared to 0.9% in the unassisted group. The ENDOANGEL-ELD system exhibited high sensitivity (89.7%), specificity (98.5%), and overall accuracy (98.2%), and was noted for its safety with no adverse events reported. These results underscore the potential of AI to enhance the early diagnosis and treatment of esophageal cancer, which could improve patient outcomes significantly.

Related Links:
Taizhou Hospital


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.